<DOC>
	<DOCNO>NCT02308085</DOCNO>
	<brief_summary>The best available evidence suggest pregnancy breast cancer increase woman 's risk develop recurrence breast cancer . In particular , recent data suggest case also woman hormone receptor-positive breast cancer . There also indication increase risk delivery complication newborn . The aim study investigate temporary interruption endocrine therapy , goal permit pregnancy , associate high risk breast cancer recurrence.The study aim also evaluate different specific indicator related fertility , pregnancy breast cancer biology young woman . A psycho-oncological companion study fertility concern , psychological well-being decisional conflict conduct interested Centers .</brief_summary>
	<brief_title>Pregnancy Outcome Safety Interrupting Therapy Women With Endocrine Responsive Breast Cancer</brief_title>
	<detailed_description>Recent decade witness delay childbearing variety reason include cultural , educational , professional . As consequence , breast cancer young woman often occur completion reproductive plan . Infertility significant impact quality life , result substantial distress young woman breast cancer influence treatment decision consistent proportion patients.The best available evidence suggest pregnancy breast cancer increase woman 's risk develop recurrence.For woman desire pregnancy breast cancer , 5-10 year endocrine therapy may substantially reduce chance conception ; however , short duration endocrine therapy population study prospective manner . Birth outcome breast cancer show different normal population , increase risk delivery complication , cesarean section , preterm birth low birth weight report . Endocrine agent potentially teratogenic : take account median half-life , wait 3 month interruption attempt conception consider safe . The limited evidence available breastfeed breast cancer report successful lactation treat breast approximately 30 % woman without detrimental effect survival . No prospective definitive data available .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Age ≥ 18 ≤ 42 year enrollment . Has receive adjuvant endocrine therapy ( SERM alone , GnRH analogue plus SERM AI ) ≥18 month ≤30 month early breast cancer . Note : Patients receive neo/adjuvant endocrine treatment within clinical trial patient receive pharmacoprevention eligible . The adjuvant endocrine therapy must stop within 1 month prior enrollment . Patient wish become pregnant . Note : Patients undergone oocyte/embryo/ovarian tissue cryopreservation breast cancer diagnosis and/or previous history assist reproductive technology ( ART ) eligible . Breast cancer patient receive endocrine therapy must histologicallyproven stage IIII , endocrineresponsive ( i.e. , estrogen and/or progesterone receptor positive , accord local definition positive , determine use immunohistochemistry ( IHC ) ) , treat curative intent . Note : Patients synchronous bilateral invasive breast cancer ( diagnose histologically within 2 month ) eligible . Patient invasive breast cancer synchronous bilateral invasive breast cancer ( diagnose histologically within 2 month ) pregnancy eligible . Patients BRCA1/2 mutation eligible . Patients could receive neo/adjuvant chemotherapy , systemic therapy ( e.g. , neo/adjuvant HER2targeted therapy ) accord institutional policy patient 's desire . Patient must premenopausal breast cancer diagnosis , determine locally document patient record . Patient must without clinical evidence locoregional distant disease , evaluate accord institutional assessment standard document patient record . Written informed consent ( IC ) trial participation must sign dated patient investigator prior enrollment . Written consent biological material submission , indicate patient inform agree tissue blood material use , transfer handling , must sign dated patient investigator prior procedure specific trial . The patient inform agree data transfer handling , accordance national data protection guideline . Patient must accessible followup . Postmenopausal patient BC diagnosis , determine locally . History hysterectomy , bilateral oophorectomy ovarian irradiation . Patients current local , locoregional relapse and/or distant metastatic breast cancer . Patients history prior ( ipsi and/or contralateral ) invasive BC . Patients previous concomitant nonbreast invasive malignancy . Exceptions limit exclusively patient follow previous malignancy , adequately treat : basal squamous cell carcinoma skin , situ nonbreast carcinoma , contra ipsilateral situ breast carcinoma , stage Ia carcinoma cervix . Concurrent disease condition would make patient inappropriate study participation serious medical disorder would interfere patient 's safety . Patients history noncompliance medical treatment and/or consider potentially unreliable . Patients psychiatric , addictive , disorder would prevent compliance protocol requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Premenopausal</keyword>
	<keyword>endocrine responsive</keyword>
	<keyword>Breast</keyword>
	<keyword>Pregnancy</keyword>
</DOC>